Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Dow
McKesson
Moodys
Merck

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Anacetrapib

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Anacetrapib: Sponsors, patents, clinical trial progress

Anacetrapib is an investigational drug.

There have been 14 clinical trials for Anacetrapib. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2012.

The most common disease conditions in clinical trials are Hypercholesterolemia, Dyslipidemias, and Hyperlipoproteinemia Type II. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Cambridge University Hospitals NHS Foundation Trust, and British Heart Foundation Cambridge Centre of Excellence.

There are thirty US patents protecting this investigational drug and three hundred and forty international patents.

Recent Clinical Trials for Anacetrapib
TitleSponsorPhase
The Effect of Anacetrapib on Vascular Function and Arterial StiffnessBritish Heart Foundation Cambridge Centre of ExcellenceN/A
The Effect of Anacetrapib on Vascular Function and Arterial StiffnessCambridge University Hospitals NHS Foundation TrustN/A
Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)Merck Sharp & Dohme Corp.Phase 3

See all Anacetrapib clinical trials

Clinical Trial Summary for Anacetrapib

Top disease conditions for Anacetrapib
Top clinical trial sponsors for Anacetrapib

See all Anacetrapib clinical trials

US Patents for Anacetrapib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Anacetrapib   Start Trial CETP inhibitors Merck & Co., Inc. (Rahway, NJ)   Start Trial
Anacetrapib   Start Trial Process for synthesizing a CETP inhibitor   Start Trial
Anacetrapib   Start Trial Polymer formulations of CETP inhibitors Merck Sharp & Dohme Corp. (Rahway, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Express Scripts
Harvard Business School
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.